A High-Throughput Liquid Chromatography Tandem Mass Spectrometry Method for the Comparative Determination of Fluticasone Propionate by Reversed-Phase Liquid Chromatography and Capillary Electrophoresis Methods in Pharmaceutical Nasal Sprays
Restricted accessResearch articleFirst published online December, 2009
A High-Throughput Liquid Chromatography Tandem Mass Spectrometry Method for the Comparative Determination of Fluticasone Propionate by Reversed-Phase Liquid Chromatography and Capillary Electrophoresis Methods in Pharmaceutical Nasal Sprays
A simple, specific, rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the analysis of fluticasone propionate (FP) in pharmaceutical formulations was developed and validated using deflazacort as internal standard (IS). The LC-MS/MS method was carried out on a C8 column (50 mm) with a mobile phase consisted of methanol:water (95:5, v/v)–100 mM formic acid–50 mM ammonium acetate (90:5:5, v/v/v). The mass spectrometry method was performed employing positive atmospheric pressure chemical ionization technique, operating in multiple reaction monitoring mode. The chromatographic separation was obtained within 1.5 min and it was linear in the concentration range of 10–1000 ng mL−1. Moreover, method validation demonstrates acceptable results for the specificity, accuracy, precision and robustness. The proposed method was successfully applied for the quantitative analysis of FP nasal sprays and the results were compared to validated liquid chromatography and capillary electrophoresis methods with photodiode array detectors showing non-significant difference (P > 0.05).
BarnesP.J.PedersenS.BusseW.W., “Efficacy and safety of inhaled corticosteroids”, Am. J. Respir. Crit. Care Med.157, S1–S53 (1998).
2.
DahlR.NielsenL.P.KipsJ.ForesiA.van CauwenbergeP.TudoricN.HowarthP.RichardsD.H.WilliamsM.PauwelsR., “Intranasal and inhaled fluticasone propionate for pollen-induced rhinitis and asthma”, Allergy60, 875–881 (2005). doi: 10.1111/j.1398-9995.2005.00819.x
3.
SzeflerS.J., “Pharmacokinetics of intranasal corticosteroids”, J. Allergy Clin. Immunol.108, S26–S31 (2001). doi: 10.1067/mai.2001.115563
4.
FrieriM., “Inflammatory issues in allergic rhinitis and asthma”, Allergy Asthma Proc.26, 163–169 (2005).
5.
PrennerB.M.SchenkelE., “Allergic rhinitis: Treatment based on patient profiles”, Am. J. Med.119, 230–237 (2006). doi: 10.1016/j.amjmed.2005.06.015
6.
BainB.M.HarrisonG.JenkinsK.D.PatemanA.J.ShenoyE.V.B., “A sensitive radioimmunoassay, incorporating solid-phase extraction, for fluticasone 17-propionate in plasma”, J. Pharm. Biomed. Anal.11, 557–561 (1993). doi: 10.1016/0731-7085(93)80005-L
7.
LiY.N.TattamB.N.BrownK.F.SealeJ.P., “A sensitive method for the quantification of fluticasone propionate in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionisation mass spectrometry”, J. Pharm. Biomed. Anal.16, 447–452 (1997). doi: 10.1016/S0731-7085(97)00073-3
8.
CallejasS.L.BiddlecombeR.A.JonesA.E.JoyceK.B.PereiraA.I.PleasanceS., “Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography-tandem mass spectrometry”, J. Chromatogr. B718, 243–250 (1998). doi: 10.1016/S0378-4347(98)00374-0
9.
LaugherL.NoctorT.G.BarrowA.OxfordJ.M.PhillipsT., “An improved method for the determination of fluticasone propionate in human plasma”, J. Pharm. Biomed. Anal.21, 749–758 (1999). doi: 10.1016/S0731-7085(99)00213-7
10.
KrishnaswamiS.MöllmannH.DerendorfH.HochhausG., “A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma”, J. Pharm. Biomed. Anal.22, 123–129 (2000). doi: 10.1016/S0731-7085(99)00246-0
11.
TaylorR.L.GrebeS.K.SinghR.J., “Quantitative, highly sensitive liquid chromatography-tandem mass spectrometry method for the detection of synthetic corticosteroids”, Clin. Chem.50, 2345–2352 (2004). doi: 10.1373/clinchem.2004.033605
12.
MascherH.J.ZechK.MascherD.G., “Sensitive determination of ciclesonide, ciclesonide-M1-metabolite and fluticasone propionate in human serum by HPLC-MS/MS with APPI”, J. Chromatogr. B869, 84–92 (2008). doi: 10.1016/j.jchromb.2008.05.015
13.
MurnameD.MartinG.P.MarriotC., “Validation of a reverse-phase high performance liquid chromatographic method for concurrent assay of a weak base (salmeterol xinafoate) and a pharmacologically active steroid (fluticasone propionate)”, J. Pharm. Biomed. Anal.40, 1149–1154 (2006). doi: 10.1016/j.jpba.2005.09.028
14.
BernalJ.L.NozalM.J.MartínM.T.Diez-MasaJ.C.CifuentesA., “Quantitation of active ingredients and excipients in nasal sprays by high-performance liquid chromatography, capillary electrophoresis and UV spectroscopy”, J. Chromatogr. A823, 423–431 (1998). doi: 10.1016/S0021-9673(98)00451-8
15.
SangoiM.S.NogueiraD.R.SilvaL.M.LealD.P.DalmoraS.L., “Validation of a stability-indicating reversed-phase LC method for the determination of fluticasone propionate in pharmaceutical formulations”, J. Liq. Chromatogr. Rel. Technol.31, 2113–2127 (2008). doi: 10.1080/10826070802225395
16.
SangoiM.S.SilvaL.M.D'AvilaF.B.DalmoraS.L., “Determination of fluticasone propionate in nasal sprays by a validated stability-indicating micellar electrokinetic chromatography method”, J. Chromatogr. Sc. (2009) in press.
17.
LeeH., “Pharmaceutical applications of liquid chromatography coupled with mass spectrometry (LC/MS)”, J. Liq. Chromatogr. Rel. Technol.28, 1161–1202 (2005). doi: 10.1081/JLC-200053022
18.
LimC.-K.LordG., “Current developments in LC-MS for pharmaceutical analysis”, Biol. Pharm. Bull.25, 547–557 (2002). doi: 10.1248/bpb.25.547
19.
VenturaR.RoigM.MonfortN.SáezP.BergésR.SeguraJ., “High-throughput and sensitive screening by ultra-performance liquid chromatography tandem mass spectrometry of diuretics and other doping agents”, Eur. J. Mass Spectrom.14(3), 191–200 (2008). doi: 10.1255/ejms.920
20.
XuX.MeiH.WangS.ZhouQ.WangG.BroskeL.PenaA.KorfmacherW.A., “A study of common discovery dosing formulation components and their potential for causing time-dependent matrix effects in high-performance liquid chromatography tandem mass spectrometry assays”, Rapid Commun. Mass Spectrom.19, 2643–2650 (2005). doi: 10.1002/rcm.2102
21.
LindegardhN.DondorpA.M.SinghasivanonP.WhiteN.J.DayN.P.J., “Validation and application of a liquid chromatographic–mass spectrometric method for determination of artesunate in pharmaceutical samples”, J. Pharm. Biomed. Anal.45, 149–153 (2007). doi: 10.1016/j.jpba.2007.04.030
22.
FeásX.YeL.HosseiniS.V.FenteC.A.CepedaA., “Development and validation of LC–MS/MS method for the determination of cyproheptadine in several pharmaceutical syrup formulations”, J. Pharm. Biomed. Anal.50, 1044–1049 (2009). doi: 10.1016/j.jpba.2009.06.006
23.
GörögS., “Drug safety, drug quality, drug analysis”, J. Pharm. Biomed. Anal.48, 247–253 (2008). doi: 10.1016/j.jpba.2007.10.038
24.
RozetE.CeccatoA.HubertC.ZiemonsE.OpreanR.RudazS.BoulangerB.HubertP., “Analysis of recent pharmaceutical regulatory documents on analytical method validation”, J. Chromatogr. A1158, 111–125 (2007). doi: 10.1016/j.chroma.2007.03.111
25.
ShabirG.A.LoughW.J.ArainS.A.BradshawT.K., “Evaluation and application of best practice in analytical method validation”, J. Liq. Chromatogr. Rel. Technol.30, 311–333 (2007). doi: 10.1080/10826070601084753
26.
Validation of Analytical Procedures: Text and Methodology Q2(R1).ICH Harmonised Tripartite Guidelines, November 2005.
27.
NiessenW.M., “Progress in liquid chromatography-mass spectrometry instrumentation and its impact on high-throughput screening”, J. Chromatogr. A.1000, 413–436 (2003). doi: 10.1016/S0021-9673(03)00506-5
28.
LiZ., High throughput analysis in support of process chemistry and formulation research and development in the pharmaceutical industry, in High Throughput Analysis in the Pharmaceutical Industry, Ed by WangP.G., CRC Press, Boca Raton, FL, USA, pp. 247–278 (2009).
